Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

0(10) TCID(50) with a constant localized radiation dose of 36 Gy given in 12 fractions. Of the six patients who have completed the study to date, three patients (colorectal, melanoma and lung cancer) experienced tumour regression in the target tumour, as well as stable disease in nontreated tumours.

The colorectal patient experienced a partial response with a more than 50% regression in the target tumour as well as stable disease in four, non-treated tumours measured at one month following treatment. A melanoma patient experienced minor regression in the target tumour as well as stable disease in two, non-treated tumours at one and two months following treatment. A lung cancer patient experienced minor regression in the target tumour, as well as stable disease in three, non-treated tumours at two months following treatment.

The treatment has been well tolerated, with mostly Grade 1 or 2 toxicities noted including fatigue, lymphopenia, fever, and neutropenia. Grade 3 toxicities including cellulitis, dysphasia and diarrhoea were related to disease progression and not to the combination treatment. Viral replication was unaffected by cellular irradiation.

The primary objective of the Phase Ia/Ib trial was to determine the maximum tolerated dose ("MTD"), dose limiting toxicity ("DLT"), and safety profile of REOLYSIN(R) when administered intratumourally to patients receiving radiation treatment. A secondary objective is to examine any evidence of anti-tumour activity. Eligible patients include those who have been diagnosed with late stage advanced or metastatic solid tumours that are refractory ("have not responded") to standard therapy or for which no curative standard therapy exists.

Clinical Trials - Actively Enrolling

At the end of the third quarter of 2007, we were actively enrolling in seven clinical trials. In the third quarter of 2007, we commenced enrollment in the following study:

U.K. Combination REOLYSIN(R) Docetaxel Clinica
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Library of Life Science Research and Enables Experiment ... SIAL ) and Ingenuity Systems today ... Web-based biological search portal for exploring dynamic gene-based ... extensive library of research findings, Your Favorite Gene ...
... Development of Accurate Blood Test for Common Genetic Disorders ... Artemis Health Inc., a privately-held company dedicated to the ... it has acquired a co-exclusive worldwide license from ... diagnostic tests based on pioneering research from the lab ...
... Australia, Jan. 27 /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS,Nasdaq: ... Quarterly Report to Shareholders,on the afternoon of Wednesday, 28th ... teleconference the following morning to review the quarter,and answer ... will be on Thursday, 29th January at 8:30am (Sydney),(Wednesday, ...
Cached Biology Technology:Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity 2Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity 3Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity 4Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 2Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 3
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
(Date:6/16/2015)... 2015 Fingerprint Cards has received an ... the company,s portfolio from one of its module partners in ... take place during the third quarter 2015. The sensors will ... . Jörgen Lantto, CEO of FPC, comments: " ... growing interest from smartphone OEMs in integrating touch fingerprint sensors ...
(Date:6/15/2015)... A new report [ 1 ] ... consumers using mobile banking applications want their mobile devices to ... instead of having to prove who they are with passwords ...   -   The Fusion of Financial Services, Mobile and ... channel used by Gen X and Gen Y to access ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... diet high in red meat, fatty products, refined grains, ... be increasing their chance of disease relapse and early ... study, published in the Aug. 15 issue of the ... with stage III colon cancer that has been treated ...
... show it is overwhelmingly likely that life began ... scientists. Professor Chandra Wickramasinghe and colleagues at ... case for panspermia - the theory that life ... across the galaxy. A recent BBC Horizon documentary ...
... torrents of microscopic waves propel white blood cells toward ... holds the potential for better understanding and treatment of ... very high-resolution light microscope, the dynamic waves are made ... protein and a second key player were already known ...
Cached Biology News:'Western' diet linked to increased risk of colon cancer recurrence 2Bursts of waves drive immune system 'soldiers' toward invaders 2Bursts of waves drive immune system 'soldiers' toward invaders 3Bursts of waves drive immune system 'soldiers' toward invaders 4
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: